# A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

> **NCT02609789** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 72 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Healthy

## Interventions

- **DRUG:** JNJ-55920839
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02609789
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609789, "A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02609789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*